1-2 of 2
Marion Jurk
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

A Phase I Open Label Dose Escalation Study of MB-CART19.1 in Relapsed and Refractory CD19+ B Cell Malignancies, Interim Preliminary Results in Pediatric ALL, Adult ALL Including CLL Cohorts

Andreas Mackensen, Linda Hanssens, Matthias Stelljes, Wolfgang A Bethge, Tobias Feuchtinger, Annette Künkele, Michael Aigner, Alisa Yakushina, Sandra Karitzky, Silke Holtkamp, Mario Assenmacher, Marion Jurk, Georg Rauser, Dina Schneider, Claudia Rossig
Journal: Blood
Blood (2021) 138 (Supplement 1): 3836.
https://doi.org/10.1182/blood-2021-152452
Published: 2021
Journal Articles

Phase I Trial of MB-CART2019.1, a Novel CD20 and CD19 Targeting Tandem Chimeric Antigen Receptor, in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Peter Borchmann, Anja Jühling, Philipp Gödel, Hyatt Balke-Want, Christoph Schmid, Francis A. Ayuk, Silke Holtkamp, Liane Preussner, Gregor Zadoyan, Linda Hanssens, Andrew Kaiser, Marion Jurk, Iris Bürger, Dina Schneider, Boro Dropulic, Toon Overstijns, Christof Scheid, MD, Udo Holtick, Stefan Miltenyi, Michael Hallek
Journal: Blood
Blood (2020) 136 (Supplement 1): 48.
https://doi.org/10.1182/blood-2020-136067
Published: 2020